Glomerular hematuria
Conditions
Interventions
experimental group:Routine treatment+Xueniaoan capsule
Control group:Conventional treatment+Xueniaoan capsule simulant
Sponsors
Zhongshan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years old, regardless of sex; (2)eGFR=30 ml/(min×1.73m2) (using CKD-EPI formula); (3) Glomerular hematuria (hereinafter referred to as renal hematuria) meets any of the following: Clinical diagnosis of glomerular hematuria: Take clean middle urine (women avoid menstrual period and 3 days before and after it, men avoid semen and prostatic fluid pollution), and send it for inspection within 30 minutes after leaving urine, and send it for urine routine and urine phase contrast microscope examination at the same time with a single sampling. At the same time, it should be satisfied: 1) the red blood cell count of urine sediment microscopy is > 3 /HP, or the red blood cell count is > 25/UL; 2) Abnormal red blood cells in urine phase contrast microscope =50%, or the information of urine red blood cells indicates heterogeneity; Pathological diagnosis confirmed primary glomerulonephritis (including IgA nephropathy, non-IgA mesangial proliferative glomerulonephritis, etc.) or secondary glomerulonephritis (including lupus nephritis, allergic purpura nephritis, etc.). (4) Those who voluntarily participate in the experiment and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Yang deficiency syndrome (mainly manifested by cold limbs); (2) Patients who have used or are using aspirin heparin or low molecular weight heparin warfarin dipyridamole and other drugs in the past week; (3) Patients who have used are using or may start to use glucocorticoid immunosuppressant (including tripterygium wilfordii alkylating agent calcineurin inhibitor mycophenolate mofetil etc.) and targeted biological agents (anti-CD20 monoclonal antibody Tatasip etc.) within 3 months before enrollment; (4) Patients with new primary or secondary tumors within 6 months before enrollment and patients receiving anti-tumor treatment; (5) Patients with severe abnormal liver function (bilirubin or transaminase more than double the normal upper limit) or severe coagulation dysfunction or severe thrombocytopenia (platelet < 50×109/L); (6) Malformation of urinary system active infection of urogenital system (including urinary tuberculosis etc.) tumor of urinary system etc. (7) Female subjects of childbearing age who have positive pregnancy test are pregnant or breast-feeding or have pregnancy and breast-feeding plans during the study period and have not taken effective contraceptive measures; (8) people with allergic constitution or allergic to experimental drugs; (9) Participated in other clinical studies within one month before the start of the study; (10)Patients with low compliance which the researchers think are not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematuria improvement rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The improvement rate of hematuria after 2, 4, 8, 12, 16 and 20 weeks of treatment.;Tcm syndrome score;Proteinuria index (UACR);Renal function index;Proteinuria index (24h UTP);Serological index;Proportion of complete remission of hematuria; | — |
Countries
China
Contacts
Public ContactDing Xiaoqiang
Zhongshan Hospital Affiliated to Fudan University
Outcome results
None listed